In addition, synergy was observed between SAHA and venetoclax in cutaneous T‐cell lymphoma patient‐derived cells (Cyrenne et al. 2017), as well as between the HDAC1/2/3‐selective inhibitor chidamide and venetoclax in AML cells (Gangping, et al. 2021). This evidence concerns the gene HDAC1 and acute myeloid leukemia.